​

Cytokinetics (CYTK) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

CYTK Stock Forecast

Cytokinetics stock forecast is as follows: an average price target of $90.00 (represents a 84.16% upside from CYTK’s last price of $48.87) and a rating consensus of 'Buy', based on 13 wall street analysts offering a 1-year stock forecast.

CYTK Price Target

The average price target for Cytokinetics (CYTK) is $90.00 based on 1-year price targets from 13 Wall Street analysts in the past 3 months, with a price target range of $120.00 to $60.00. This represents a potential 84.16% upside from CYTK's last price of $48.87.

CYTK Analyst Ratings

Buy

According to 13 Wall Street analysts, Cytokinetics's rating consensus is 'Buy'. The analyst rating breakdown for CYTK stock is 0 'Strong Buy' (0.00%), 11 'Buy' (84.62%), 2 'Hold' (15.38%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Cytokinetics Price Target by Analyst

DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Oct 17, 2024Joseph PantginisH.C. Wainwright$120.00$55.28117.08%145.55%
Sep 03, 2024Paul ChoiGoldman Sachs$60.00$54.569.97%22.77%
Jun 10, 2024Yasmeen RahimiPiper Sandler$107.00$53.21101.09%118.95%
Jun 04, 2024Mayank MamtaniB.Riley Financial$92.00$48.7088.91%88.25%
May 28, 2024Jason ButlerJMP Securities$78.00$48.3061.49%59.61%
May 23, 2024Joseph PantginisH.C. Wainwright$90.00$48.7184.77%84.16%
May 23, 2024Serge BelangerNeedham$72.00$59.2321.56%47.33%
May 23, 2024Akash TewariJefferies$85.00$59.2343.51%73.93%
May 23, 2024Carter GouldBarclays$95.00$59.2360.39%94.39%
May 09, 2024Justin KimOppenheimer$106.00$65.2762.40%116.90%
May 09, 2024Jason ButlerJMP Securities$106.00$65.2762.40%116.90%
Apr 05, 2024Salim SyedMizuho Securities$99.00$72.7436.10%102.58%
Dec 23, 2022Needham$58.00$45.5927.22%18.68%
Dec 20, 2022Truist Financial$60.00$45.2232.69%22.77%
Aug 23, 2022Dane LeoneRaymond James$63.00$52.1720.76%28.91%
Jun 09, 2022Yasmeen RahimiPiper Sandler$72.00$38.8485.38%47.33%
Apr 30, 2022Joseph PantginisH.C. Wainwright$75.00$39.8788.11%53.47%
Dec 20, 2021Carter GouldBarclays$52.00$39.5031.65%6.40%
Nov 18, 2021Dane LeoneRaymond James$54.00$40.7332.58%10.50%
Oct 08, 2021Jeffrey HungMorgan Stanley$45.00$38.0118.39%-7.92%

The latest Cytokinetics stock forecast, released on Oct 17, 2024 by Joseph Pantginis from H.C. Wainwright, set a price target of $120.00, which represents a 117.08% increase from the stock price at the time of the forecast ($55.28), and a 145.55% increase from CYTK last price ($48.87).

Cytokinetics Price Target by Period

1M3M12M
# Anlaysts-112
Avg Price Target-$120.00$92.50
Last Closing Price$48.87$48.87$48.87
Upside/Downside-100.00%145.55%89.28%

In the current month, the average price target of Cytokinetics stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Cytokinetics's last price of $48.87. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

DateCompanyPrevious RatingNew RatingRating Change
Nov 19, 2024Goldman SachsNeutralNeutralHold
Nov 18, 2024H.C. WainwrightBuyBuyHold
Oct 17, 2024H.C. WainwrightBuyBuyHold
Sep 20, 2024H.C. WainwrightBuyBuyHold
Sep 03, 2024Goldman SachsNeutralNeutralHold
Aug 13, 2024Goldman SachsNeutralDowngrade
Jun 10, 2024Piper SandlerOverweightOverweightHold
Jun 04, 2024B. RileyBuyBuyHold
May 23, 2024H.C. WainwrightBuyBuyHold
May 23, 2024NeedhamBuyBuyHold
May 23, 2024JefferiesBuyBuyHold
May 23, 2024BarclaysOverweightOverweightHold
May 14, 2024Bank of America SecuritiesNeutralNeutralHold
May 09, 2024OppenheimerOutperformOutperformHold
May 09, 2024JMP SecuritiesOutperformOutperformHold
Apr 03, 2024Bank of America SecuritiesNeutralNeutralHold
Aug 15, 2023Cantor FitzgeraldOverweightInitialise
Aug 15, 2023BarclaysOverweightInitialise
Aug 15, 2023OppenheimerOutperformInitialise
Aug 15, 2023SVB LeerinkOutperformInitialise
Dec 23, 2022NeedhamBuyBuyHold
Dec 14, 2022NeedhamBuyInitialise
Dec 13, 2022Piper SandlerOverweightOverweightHold
Aug 23, 2022Raymond JamesOutperformOutperformHold
Jun 09, 2022Piper SandlerOverweightOverweightHold
Apr 30, 2022H.C. WainwrightBuyBuyHold

Cytokinetics's last stock rating was published by Goldman Sachs on Nov 19, 2024. The company gave CYTK a "Neutral" rating, the same as its previous rate.

Cytokinetics Financial Forecast

Cytokinetics Revenue Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
Revenue-------------$378.00K$867.00K$4.61M$1.96M$2.52M$88.97M$1.15M$55.60M$5.44M$2.84M$6.55M$6.72M$41.69M$3.59M$3.83M$5.21M$6.05M
Avg Forecast$106.50M$68.94M$45.96M$30.64M$16.73M$3.58M$1.75M$508.00K$10.22M$1.21M$7.61M$912.85K$7.62M$20.24M$5.67M$2.08M$7.10M$3.51M$3.73M$4.34M$5.80M$5.98M$5.52M$6.57M$23.76M$4.02M$4.07M$5.01M$7.20M$7.52M
High Forecast$106.50M$68.94M$45.96M$30.64M$16.73M$3.58M$1.75M$508.00K$34.20M$1.25M$7.61M$912.92K$39.92M$20.24M$5.67M$2.08M$7.10M$3.51M$3.73M$4.34M$5.80M$5.98M$5.52M$6.57M$23.76M$4.02M$4.07M$5.01M$7.20M$7.52M
Low Forecast$106.50M$68.94M$45.96M$30.64M$16.73M$3.58M$1.75M$508.00K$346.63K$1.17M$7.61M$912.77K$319.32K$20.24M$5.67M$2.08M$7.10M$3.51M$3.73M$4.34M$5.80M$5.98M$5.52M$6.57M$23.76M$4.02M$4.07M$5.01M$7.20M$7.52M
# Analysts1111111311551011559544755107999955
Surprise %-------------0.02%0.15%2.21%0.28%0.72%23.84%0.26%9.58%0.91%0.52%1.00%0.28%10.38%0.88%0.76%0.72%0.81%

Cytokinetics's average Quarter revenue forecast for Dec 23 based on 11 analysts is $7.62M, with a low forecast of $319.32K, and a high forecast of $39.92M. CYTK's average Quarter revenue forecast represents a 1914.79% increase compared to the company's last Quarter revenue of $378.00K (Sep 23).

Cytokinetics EBITDA Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts1111111311551011559544755107999955
EBITDA-------------$-115.43M$-115.27M$-118.05M$-121.11M$-102.89M$-10.01M$-77.44M$-21.35M$-68.51M$-54.07M$-39.78M$-33.79M$6.80M$-30.56M$-29.23M$-21.98M$-22.57M
Avg Forecast$-106.50M$-68.94M$-45.96M$-30.64M$-16.73M$-3.58M$-1.75M$-508.00K$-10.22M$-1.21M$-7.61M$-60.82M$-7.62M$-20.24M$-5.67M$-65.05M$-33.21M$-3.51M$-3.73M$-69.57M$-5.80M$-5.98M$-5.52M$-34.30M$-23.76M$-4.02M$-4.07M$-19.88M$-7.20M$-7.52M
High Forecast$-106.50M$-68.94M$-45.96M$-30.64M$-16.73M$-3.58M$-1.75M$-508.00K$-346.63K$-1.17M$-7.61M$-48.66M$-319.32K$-20.24M$-5.67M$-52.04M$-26.57M$-3.51M$-3.73M$-55.66M$-5.80M$-5.98M$-5.52M$-27.44M$-23.76M$-4.02M$-4.07M$-15.90M$-7.20M$-7.52M
Low Forecast$-106.50M$-68.94M$-45.96M$-30.64M$-16.73M$-3.58M$-1.75M$-508.00K$-34.20M$-1.25M$-7.61M$-72.99M$-39.92M$-20.24M$-5.67M$-78.06M$-39.85M$-3.51M$-3.73M$-83.49M$-5.80M$-5.98M$-5.52M$-41.16M$-23.76M$-4.02M$-4.07M$-23.85M$-7.20M$-7.52M
Surprise %-------------5.70%20.35%1.81%3.65%29.34%2.68%1.11%3.68%11.45%9.80%1.16%1.42%-1.69%7.50%1.47%3.06%3.00%

9 analysts predict CYTK's average Quarter EBITDA for Dec 20 to be $-23.76M, with a high of $-23.76M and a low of $-23.76M. This is -449.57% lower than Cytokinetics's previous annual EBITDA (Sep 20) of $6.80M.

Cytokinetics Net Income Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts1111111311551011559544755107999955
Net Income-------------$-129.42M$-128.64M$-129.44M$-131.46M$-176.18M$-28.77M$-101.03M$-39.06M$-76.09M$-61.55M$-47.10M$-43.93M$-3.17M$-40.78M$-39.41M$-30.64M$-29.57M
Avg Forecast$-75.32M$-103.56M$-122.39M$-129.45M$-137.30M$-156.52M$-151.52M$-150.05M$-146.43M$-145.29M$-124.34M$-69.04M$-112.80M$-87.42M$-134.09M$-73.84M$-47.56M$-127.14M$-112.47M$-78.98M$-92.67M$-84.77M$-72.10M$-40.61M$-47.44M$-36.87M$-62.11M$-26.80M$-48.07M$-53.75M
High Forecast$-75.32M$-103.56M$-122.39M$-129.45M$-137.30M$-156.52M$-151.52M$-134.93M$-69.67M$-145.29M$-124.34M$-55.24M$-55.85M$-87.42M$-134.09M$-59.08M$-38.05M$-127.14M$-112.47M$-63.18M$-92.67M$-84.77M$-72.10M$-32.49M$-47.44M$-36.87M$-62.11M$-21.44M$-48.07M$-53.75M
Low Forecast$-75.32M$-103.56M$-122.39M$-129.45M$-137.30M$-156.52M$-151.52M$-170.99M$-188.94M$-145.29M$-124.34M$-82.85M$-160.98M$-87.42M$-134.09M$-88.61M$-57.07M$-127.14M$-112.47M$-94.77M$-92.67M$-84.77M$-72.10M$-48.73M$-47.44M$-36.87M$-62.11M$-32.15M$-48.07M$-53.75M
Surprise %-------------1.48%0.96%1.75%2.76%1.39%0.26%1.28%0.42%0.90%0.85%1.16%0.93%0.09%0.66%1.47%0.64%0.55%

Cytokinetics's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. CYTK's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

Cytokinetics SG&A Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts1111111311551011559544755107999955
SG&A-------------$40.11M$39.72M$49.66M$53.97M$48.22M$42.72M$33.07M$33.81M$26.20M$21.20M$15.60M$13.91M$12.30M$14.16M$12.45M$10.58M$9.75M
Avg Forecast$611.97M$396.18M$264.12M$176.08M$96.12M$20.58M$10.05M$2.92M$58.75M$6.98M$43.71M$5.25M$43.76M$116.32M$32.55M$11.98M$40.80M$20.15M$21.44M$24.97M$33.34M$34.39M$31.71M$37.77M$136.56M$23.08M$23.40M$28.77M$41.35M$43.21M
High Forecast$611.97M$396.18M$264.12M$176.08M$96.12M$20.58M$10.05M$2.92M$196.53M$7.20M$43.71M$5.25M$229.38M$116.32M$32.55M$11.98M$40.80M$20.15M$21.44M$24.97M$33.34M$34.39M$31.71M$37.77M$136.56M$23.08M$23.40M$28.77M$41.35M$43.21M
Low Forecast$611.97M$396.18M$264.12M$176.08M$96.12M$20.58M$10.05M$2.92M$1.99M$6.75M$43.71M$5.25M$1.84M$116.32M$32.55M$11.98M$40.80M$20.15M$21.44M$24.97M$33.34M$34.39M$31.71M$37.77M$136.56M$23.08M$23.40M$28.77M$41.35M$43.21M
Surprise %-------------0.34%1.22%4.15%1.32%2.39%1.99%1.32%1.01%0.76%0.67%0.41%0.10%0.53%0.61%0.43%0.26%0.23%

Cytokinetics's average Quarter SG&A projection for Dec 23 is $43.76M, based on 11 Wall Street analysts, with a range of $1.84M to $229.38M. The forecast indicates a 9.11% rise compared to CYTK last annual SG&A of $40.11M (Sep 23).

Cytokinetics EPS Forecast

Dec 26Sep 26Jun 26Mar 26Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19
# Analysts1111111311551011559544755107999955
EPS-------------$-1.35$-1.34$-1.36$-1.39$-1.88$-0.34$-1.19$-0.46$-0.95$-0.86$-0.66$-0.62$-0.05$-0.68$-0.66$-0.52$-0.50
Avg Forecast$-0.64$-0.88$-1.04$-1.10$-1.17$-1.33$-1.29$-1.27$-1.24$-1.23$-1.06$-1.14$-0.96$-0.74$-1.14$-1.20$-1.21$-1.16$-1.03$-0.94$-0.85$-0.78$-0.66$-0.58$-0.43$-0.34$-0.57$-0.50$-0.44$-0.49
High Forecast$-0.64$-0.88$-1.04$-1.10$-1.17$-1.33$-1.29$-1.15$-0.59$-1.23$-1.06$-1.14$-0.47$-0.74$-1.14$-1.20$-1.21$-1.16$-1.03$-0.94$-0.85$-0.78$-0.66$-0.58$-0.43$-0.34$-0.57$-0.50$-0.44$-0.49
Low Forecast$-0.64$-0.88$-1.04$-1.10$-1.17$-1.33$-1.29$-1.45$-1.61$-1.23$-1.06$-1.14$-1.37$-0.74$-1.14$-1.20$-1.21$-1.16$-1.03$-0.94$-0.85$-0.78$-0.66$-0.58$-0.43$-0.34$-0.57$-0.50$-0.44$-0.49
Surprise %-------------1.82%1.18%1.13%1.15%1.62%0.33%1.26%0.54%1.22%1.30%1.13%1.43%0.15%1.20%1.32%1.17%1.02%

According to undefined Wall Street analysts, Cytokinetics's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to CYTK previous annual EPS of $NaN (undefined).

Cytokinetics Peer Comparison by Price Target

TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
BDTXBlack Diamond Therapeutics$2.50$20.00700.00%Buy
INZYInozyme Pharma$2.94$16.00444.22%Buy
XFORX4 Pharmaceuticals$0.74$3.67395.95%Buy
RLAYRelay Therapeutics$4.50$18.00300.00%Buy
ABOSAcumen Pharmaceuticals$1.96$7.00257.14%Buy
ARVNArvinas$19.10$58.50206.28%Buy
TERNTerns Pharmaceuticals$6.80$18.67174.56%Buy
PLRXPliant Therapeutics$14.37$35.50147.04%Buy
STOKStoke Therapeutics$12.10$26.50119.01%Buy
AMLXAmylyx Pharmaceuticals$4.28$8.2592.76%Buy
CYTKCytokinetics$47.78$90.0088.36%Buy
DYNDyne Therapeutics$26.16$49.0087.31%Buy
EWTXEdgewise Therapeutics$30.17$46.2553.30%Buy
RVMDRevolution Medicines$45.16$65.6745.42%Buy
BPMCBlueprint Medicines$96.48$122.6027.07%Buy

CYTK Forecast FAQ

Is Cytokinetics a good buy?

Yes, according to 13 Wall Street analysts, Cytokinetics (CYTK) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 11 'Buy' recommendations, accounting for 84.62% of CYTK's total ratings.

What is CYTK's price target?

Cytokinetics (CYTK) average price target is $90 with a range of $60 to $120, implying a 84.16% from its last price of $48.87. The data is based on 13 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Cytokinetics stock go up soon?

According to Wall Street analysts' prediction for CYTK stock, the company can go up by 84.16% (from the last price of $48.87 to the average price target of $90), up by 145.55% based on the highest stock price target, and up by 22.77% based on the lowest stock price target.

Can Cytokinetics stock reach $70?

CYTK's average twelve months analyst stock price target of $90 supports the claim that Cytokinetics can reach $70 in the near future.

What are Cytokinetics's analysts' financial forecasts?

Cytokinetics's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $22.56M (high $22.56M, low $22.56M), average EBITDA is $-22.563M (high $-22.563M, low $-22.563M), average net income is $-595M (high $-580M, low $-616M), average SG&A $129.66M (high $129.66M, low $129.66M), and average EPS is $-5.059 (high $-4.931, low $-5.237). CYTK's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $252.04M (high $252.04M, low $252.04M), average EBITDA is $-252M (high $-252M, low $-252M), average net income is $-431M (high $-431M, low $-431M), average SG&A $1.45B (high $1.45B, low $1.45B), and average EPS is $-3.66 (high $-3.66, low $-3.66).

Did the CYTK's actual financial results beat the analysts' financial forecasts?

Based on Cytokinetics's last annual report (Dec 2023), the company's revenue was $7.53M, which missed the average analysts forecast of $35.61M by -78.85%. Apple's EBITDA was $-526M, beating the average prediction of $-98.573M by 433.86%. The company's net income was $-526M, beating the average estimation of $-408M by 28.93%. Apple's SG&A was $173.61M, missing the average forecast of $204.61M by -15.15%. Lastly, the company's EPS was $-5.45, beating the average prediction of $-4.04 by 34.90%. In terms of the last quarterly report (Sep 2023), Cytokinetics's revenue was $378K, missing the average analysts' forecast of $20.24M by -98.13%. The company's EBITDA was $-115M, beating the average prediction of $-20.241M by 470.26%. Cytokinetics's net income was $-129M, beating the average estimation of $-87.421M by 48.04%. The company's SG&A was $40.11M, missing the average forecast of $116.32M by -65.52%. Lastly, the company's EPS was $-1.35, beating the average prediction of $-0.743 by 81.73%